Clinical trials: Epilepsy (Treatment Refractory)
Refractory Partial Seizures
Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.
- Trial name
- NCT04558580
- Testing
- Rufinamide
- Where
- United States
- Sponsor
- University of South Alabama
Refractory Epilepsy
Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy
Refractory epilepsies caused by an autoimmune mechanisms lead in children to progressive neurodegeneration. Immunomodulation therapy is effective only in a half of such cases. New approaches are undertaken.
- Trial name
- EPIMSC (NCT03676569)
- Testing
- ADRC transplantation in autoimmune refractory epilepsy
- Volunteers
- 6 people
- Sponsor
- Mossakowski Medical Research Centre Polish Academy of Sciences
Epilepsies, Partial
Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept
The purpose of this study is to investigate a novel stimulation protocol of repetitive transcranial magnetic stimulation (rTMS) for the treatment of unifocal neocortical epilepsy, namely continuous thetaburst stimulation (cTBS).
- Trial name
- NCT02635633
- Testing
- continuous thetaburst stimulation
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- University Hospital, Ghent
Epilepsy, Partial
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152503
- Testing
- Seletracetam (UCB44212)
- Where
- 17 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- UCB Pharma SA
Epilepsy (treatment Refractory)
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population.
- Trial name
- PREDICT-PFO (NCT06863350)
- Testing
- patent foramen ovale closure
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sichuan University
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Epilepsy Intractable
Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy
The aim of this study is to investigate the effects of cathodal transcranial direct current stimulation in the management of seizures in subjects with focal refractory epilepsy.
- Trial name
- NCT04325360
- Testing
- Cathodal Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Campinas, Brazil
Epilepsy, Lennox Gastaut Syndrome
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or…
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
- Trial name
- NCT05339126
- Testing
- RNS System
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- NeuroPace
Inherited Mitochondrial Disease
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical…
- Trial name
- NCT05218655
- Testing
- Vatiquinone
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- PTC Therapeutics
Refractory Epilepsy
Expanded Use of Cannabidiol Oral Solution
To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.
- Trial name
- NCT03196934
- Testing
- Cannabidiol oral solution
- Sponsor
- MultiCare Health System Research Institute
Epilepsy
Cannabinoid Therapy for Pediatric Epilepsy
This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome.
- Trial name
- NCT02983695
- Testing
- TIL-TC150
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Refractory Epilepsy
Long Term Follow-up of Hippocampal DBS for Refractory Epilepsy
Follow up of the patients at Ghent University Hospital treated with hippocampal DBS for refractory epilepsy. Endpoints: Long term evaluation of the effects of hippocampal DBS on seizure frequency and cognition Evaluation of the…
- Trial name
- NCT03404128
- Testing
- Questionnaires
- Volunteers
- 6 people
- Sponsor
- University Hospital, Ghent
Developmental and Epileptic Encephalopathies, Epileptic Spasms
Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for…
- Conditions
- Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
- Trial name
- NCT06700811
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Heather Olson
Refractory Focal Epilepsy
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy
Evaluate the safety, tolerability, and preliminary efficacy of GD-iEXo-002 nasal drops in the treatment of focal refractory epilepsy
- Trial name
- NCT05886205
- Testing
- iPSC-Exos
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking Union Medical College Hospital
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of the study is to evaluate the efficacy and safety of topiramate in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236873
- Testing
- topiramate
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy (Treatment Refractory)
Trigeminal Nerve Stimulation of the Treatment of Epilepsy
Background: Epilepsy is a common neurological disorder among veterans. Medications do not control seizures in 1/3rd of patients, who often require neurostimulation. However, current neurostimulation devices are invasive.
- Trial name
- NCT07220161
- Testing
- Trigeminal nerve stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine
Epilepsy
Clinical Trial of MgLiTT for Medical Refractory Epilepsy
Multicenter, open-label, prospective designed study to characterize the performance of MRI-guided laser interstitial thermal therapy (MgLiTT) using the Sinovation Laser Ablation System for the treatment of medical refractory…
- Trial name
- NCT04569071
- Testing
- Sinovation Laser Ablation System
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Beijing Tiantan Hospital
Epilepsy
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.
- Trial name
- NCT00175864
- Testing
- Seletracetam (ucb 44212)
- Sponsor
- UCB Pharma
Epilepsy
Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in pediatric epilepsy
- Trial name
- NCT00918424
- Testing
- Oxcarbazepine Extended Release
- Where
- 6 sites in United States
- Sponsor
- Supernus Pharmaceuticals, Inc.